These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Comparison on efficacy in treating liver fibrosis of chronic hepatitis B between Astragalus Polygonum anti-fibrosis decoction and jinshuibao capsule].
    Author: Chen H, Weng L.
    Journal: Zhongguo Zhong Xi Yi Jie He Za Zhi; 2000 Apr; 20(4):255-7. PubMed ID: 11789260.
    Abstract:
    OBJECTIVE: To observe the efficacy of Astragalus-Polygonum Anti-Fibrosis Decoction (APAFD) and Jinshuibao capsule (JSBC) in treating liver fibrosis of chronic hepatitis B. METHODS: Ninety-two liver fibrosis of chronic hepatitis B patients were randomly divided into group A and B. Patients in group A received APAFD for 48 weeks, and in group B, they received JSBC for 48 weeks. The effects were observed on the change of hyaluronic acid (HA), laminin (LN), pro-collagen III (PCIII) and collagen IV (CIV) as well as liver functional tests and liver biochemical parameters before and after treatment. RESULTS: Levels of serum HA, LN, PCIII and CIV in the group A declined more obviously than that of group B, the difference was significant (P < 0.01). The liver functional tests such as total bilirubin (TB), alanine aminotransferase (ALT), albumin/globulin ratio, hepatitis related serum biochemical parameters such as cholylglycine (CG), serum ferritin (SF), prealbumin (PA) of group A all were improved more significantly than that of group B (P < 0.01). CONCLUSION: APAFD is more effective than JSBC in treating liver fibrosis of chronic hepatitis B, and in the inhibition of hepatic inflammation, it is a good composite Chinese herbal preparation against liver fibrosis.
    [Abstract] [Full Text] [Related] [New Search]